05-725
Anti-53BP1 Antibody, clone BP18
ascites fluid, clone BP18, Upstate®
Synonym(s):
Anti-Anti-53BP1, Anti-Anti-TDRD30, Anti-Anti-p202, Anti-Anti-p53BP1
Sign Into View Organizational & Contract Pricing
Select a Size
200 μL
€444.00
€444.00
Estimated to ship onApril 12, 2025
A recombinant, preservative-free antibody is available for your target. Try ZRB1153
Request a Bulk Order
All Photos(1)
Select a Size
Change View
200 μL
€444.00
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
€444.00
Estimated to ship onApril 12, 2025
A recombinant, preservative-free antibody is available for your target. Try ZRB1153
Request a Bulk Order
Recommended Products
biological source
mouse
Quality Level
antibody form
ascites fluid
antibody product type
primary antibodies
clone
BP18, monoclonal
species reactivity
mouse, human
manufacturer/tradename
Upstate®
technique(s)
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgM
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... TP53BP1(7158)
mouse ... Trp53Bp1(27223)
Specificity
53BP1
Immunogen
Mix of three GST fusion proteins corresponding to residues 1-337, 338-671, and 1331-1664, respectively, of human 53BP1
Application
Detect 53BP1 with Anti-53BP1 Antibody, clone BP18 (Mouse Monoclonal Antibody), that has been shown to work in IP & WB.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Transcription Factors
Quality
routinely evaluated by immunoblot on whole cell lysates from HeLa cells
Target description
~250kDa
Physical form
Ascites
mouse ascites IgM containing 0.05% sodium azide and 30% glycerol
Storage and Stability
2 years at -20°C
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Maria Pinkerneil et al.
Targeted oncology, 11(6), 783-798 (2016-06-03)
Targeting of class I histone deacetylases (HDACs) exerts antineoplastic actions in various cancer types by modulation of transcription, upregulation of tumor suppressors, induction of cell cycle arrest, replication stress and promotion of apoptosis. Class I HDACs are often deregulated in
Maria Pinkerneil et al.
Molecular cancer therapeutics, 15(2), 299-312 (2016-01-17)
Class I histone deacetylases HDAC1 and HDAC2 contribute to cell proliferation and are commonly upregulated in urothelial carcinoma. To evaluate whether specific inhibition of these enzymes might serve as an appropriate therapy for urothelial carcinoma, siRNA-mediated knockdown and specific pharmacologic
Irene M Ward et al.
Molecular and cellular biology, 23(7), 2556-2563 (2003-03-18)
53BP1 is a p53 binding protein of unknown function that binds to the central DNA-binding domain of p53. It relocates to the sites of DNA strand breaks in response to DNA damage and is a putative substrate of the ataxia
Maria Pinkerneil et al.
Methods in molecular biology (Clifton, N.J.), 1655, 289-317 (2017-09-11)
Mutations, dysregulation, and dysbalance of epigenetic regulators are especially frequent in urothelial carcinoma (UC) compared to other malignancies. Accordingly, targeting epigenetic regulators may provide a window of opportunity particularly in anticancer therapy of UC. In general, these epigenetic regulators comprise
I Rappold et al.
The Journal of cell biology, 153(3), 613-620 (2001-05-02)
The tumor suppressor p53 binding protein 1 (53BP1) binds to the DNA-binding domain of p53 and enhances p53-mediated transcriptional activation. 53BP1 contains two breast cancer susceptibility gene 1 COOH terminus (BRCT) motifs, which are present in several proteins involved in
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
